Oppenheimer Increases Savara (NASDAQ:SVRA) Price Target to $15.00

Savara (NASDAQ:SVRA) had its target price boosted by Oppenheimer from $11.00 to $15.00 in a research note issued to investors on Wednesday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

A number of other analysts have also commented on the company. Piper Sandler boosted their target price on Savara from $7.00 to $16.00 and gave the company an overweight rating in a research report on Monday, March 4th. JMP Securities restated a market outperform rating and set a $8.00 price objective on shares of Savara in a report on Monday, May 6th. HC Wainwright reiterated a buy rating and set a $6.00 price objective on shares of Savara in a report on Monday, May 13th. Finally, Evercore ISI lowered their target price on shares of Savara from $10.00 to $7.00 and set an outperform rating on the stock in a report on Thursday, May 16th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of Buy and a consensus target price of $11.00.

Savara Price Performance

Savara stock opened at $4.03 on Wednesday. The company has a current ratio of 14.90, a quick ratio of 14.90 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $556.91 million, a PE ratio of -10.89 and a beta of 0.70. Savara has a 12 month low of $2.63 and a 12 month high of $5.70. The stock has a 50-day moving average price of $4.30 and a two-hundred day moving average price of $4.63.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Analysts expect that Savara will post -0.41 EPS for the current year.

Institutional Trading of Savara

A number of hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC increased its position in Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after buying an additional 2,114 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Savara by 15.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock valued at $168,000 after buying an additional 4,625 shares during the period. CANADA LIFE ASSURANCE Co bought a new stake in Savara during the first quarter worth about $35,000. AJOVista LLC bought a new stake in Savara during the fourth quarter worth about $40,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Savara by 66.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 26,035 shares of the company’s stock worth $130,000 after purchasing an additional 10,381 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.